Telomir Pharmaceuticals, Inc. (TELO) Financial Statements (2026 and earlier)

Company Profile

Business Address 100 SE 2ND ST
MIAMI, FL 33131
State of Incorp. FL
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments7,286,6707,329,298754,323402,9991,266,131834,638
Cash and cash equivalent7,286,6707,329,298754,323402,9991,266,131834,638
Prepaid expense54,69172,81975,28888,18957,87477,347
Other undisclosed current assets      130,000
Total current assets:7,341,3617,402,117829,611491,1881,324,0051,041,985
Noncurrent Assets
TOTAL ASSETS:7,341,3617,402,117829,611491,1881,324,0051,041,985
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:536,769329,375254,956558,862587,536506,479
Other undisclosed accounts payable and accrued liabilities536,769329,375254,956558,862587,536506,479
Debt      
Other liabilities318,23493,43293,43293,43293,432 
Other undisclosed current liabilities 572,988    93,432
Total current liabilities:1,427,991422,807348,388652,294680,968599,911
Noncurrent Liabilities
Total liabilities:1,427,991422,807348,388652,294680,968599,911
Equity
Equity, attributable to parent5,913,3706,979,310481,223(161,106)643,037442,074
Additional paid in capital46,923,43345,928,18038,327,79932,615,58031,239,89528,140,559
Accumulated deficit(41,010,063)(38,948,870)(37,846,576)(32,776,686)(30,596,858)(27,698,485)
Total equity:5,913,3706,979,310481,223(161,106)643,037442,074
TOTAL LIABILITIES AND EQUITY:7,341,3617,402,117829,611491,1881,324,0051,041,985

Income Statement (P&L) (USD)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Operating expenses(2,134,681)(1,146,476)(5,069,910)(2,187,782)(2,905,435)(6,006,178)
Other undisclosed operating income (loss)    4,375,654(130,000) 
Operating income (loss):(2,134,681)(1,146,476)(5,069,910)2,187,872(3,035,435)(6,006,178)
Nonoperating income72,10044,1821,362  15,445
Investment income, nonoperating 72,10044,1821,362   
Other nonoperating income      
Interest and debt expense  (1,342) 1 
Other undisclosed income from continuing operations before equity method investments, income taxes 1,388   4,297,604 
Net income (loss):(2,061,193)(1,102,294)(5,069,890)2,187,8721,262,170(5,990,733)
Other undisclosed net income (loss) attributable to parent   (4,367,700)(4,160,543) 
Net loss available to common stockholders, diluted:(2,061,193)(1,102,294)(5,069,890)(2,179,828)(2,898,373)(5,990,733)

Comprehensive Income (USD)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Net income (loss):(2,061,193)(1,102,294)(5,069,890)2,187,8721,262,170(5,990,733)
Comprehensive income (loss), net of tax, attributable to parent:(2,061,193)(1,102,294)(5,069,890)2,187,8721,262,170(5,990,733)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: